Merck (MRK) Net Income towards Common Stockholders (QoQ) (2009 - 2026)
Merck (MRK) Net Income towards Common Stockholders (QoQ) (2009 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
| 1 |
Eli Lilly |
1,066.16 Bn |
1,060.88 Bn |
16.22 Bn |
| 2 |
Johnson & Johnson |
611.69 Bn |
589.64 Bn |
15.96 Bn |
| 3 |
AbbVie |
444.34 Bn |
434.99 Bn |
10.78 Bn |
| 4 |
Astrazeneca |
284.94 Bn |
277.05 Bn |
12.61 Bn |
| 5 |
Merck |
224.23 Bn |
218.58 Bn |
12.09 Bn |
| 6 |
Amgen |
195.12 Bn |
183.08 Bn |
5.87 Bn |
| 7 |
Gilead Sciences |
156.45 Bn |
148.73 Bn |
5.52 Bn |
| 8 |
Pfizer |
136.01 Bn |
123.24 Bn |
-1.21 Bn |
| 9 |
Novartis Ag |
113.45 Bn |
113.67 Bn |
- |
| 10 |
Biogen |
30.87 Bn |
26.59 Bn |
1.82 Bn |
| Date | Value |
|---|
| Mar 31, 2026 |
-242.10% |
| Dec 31, 2025 |
-48.82% |
| Sep 30, 2025 |
30.69% |
| Jun 30, 2025 |
-12.92% |
| Mar 31, 2025 |
35.82% |
| Dec 31, 2024 |
18.44% |
| Sep 30, 2024 |
-42.12% |
| Jun 30, 2024 |
14.56% |
| Mar 31, 2024 |
488.83% |
| Dec 31, 2023 |
-125.81% |
| Sep 30, 2023 |
180.01% |
| Jun 30, 2023 |
-310.16% |
| Jun 30, 2021 |
-24.03% |
| Mar 31, 2021 |
-16.44% |
| Dec 31, 2020 |
-15.24% |
| Sep 30, 2020 |
-6.66% |
| Jun 30, 2020 |
-79.47% |
| Mar 31, 2020 |
278.04% |
| Dec 31, 2019 |
-194.81% |
| Sep 30, 2019 |
-27.87% |
